Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert S. who wrote (15993)	8/20/2002 10:00:48 PM
From: aknahow	Respond to of 17367

Indeed, I loved the article you posted. ""Rather, such variables as genetic predisposition, parental predilection, sibling influence, peer pressure, educational experience and life impressions all shape the personality preferences that, in conjunction with numerous social and cultural influences, lead us to our beliefs. We then sort through the body of data and select those that most confirm what we already believe, and ignore or rationalize away those that do not."" "peer pressure, ... all shape the personality preferences that,..........in conjunction with numerous social and cultural influences, lead us to our beliefs." Xoma is generally ignored at S.I. Do you think the above is in any way related?

To: Robert S. who wrote (15993)	8/22/2002 1:43:56 PM
From: aknahow	Respond to of 17367

Do you have any idea of why I loved the article you posted? You may be a self proclaimed skeptic, but you are part of a large crowd on S.I.

To: Robert S. who wrote (15993)	8/25/2002 1:10:43 AM
From: aknahow	Respond to of 17367

Robert S. you may be this boards self proclaimed sceptic but you are the one that has followed the crowd at S.I. Most biotech posters go with the popular view which amounts to anything but Xoma. Microcide, CBST, BTRN, even BGEN. The leader speaks and the sheep, like you follow. Whether Neuprex, BPI or LBP ever come to anything is still an open question but they represent huge platforms. A BLA has not yet been filed for Raptiva but Xanelim also is a major platform. Interesting how some ignore the facts and parrot the Xoma failure line. Understanding the DNA and BAX partnerships would indicate that Xoma has not failed. Some are bitter because they lost money. Others because they don't like some of the management they once knew. So tell us what you are uniquely skeptical about? We have already heard how proteins were out and small molecules were in. The trauma trial failed. The DNA failure to use the required ration of DNA produced Xanelim. So please come up with something new.